BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
3D cell culture systems have recently as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). Join us Read more…
The skin microbiota refers to the microorganisms living on the skin, on the surface of the epidermis, but also in the dermis and the hypodermis (Nakatsuji et al., 2013). On 1 cm2 of human skin, Read more…
Nous sommes heureux de vous annoncer que le Ministère de l’Enseignement Supérieur et de la Recherche a accordé à HCS Pharma l’agrément au Crédit d’Impôt Recherche (CIR) jusqu’en 2023, en regard de nos activités de R&D. Read more…
We are glad to share with you confocal microscopy pictures showing the interactions between two proteins (complexes are the red spots) at the surface of breast cancer cells (MDA-MB-231) cultivated in 3D in BIOMIMESYS matrix. Read more…
Oxidative stress is a pathological state characterized by a cellular submergence by Reactive Oxygen Species (ROS) such as free radicals. ROS are naturally produced in small quantities by the cellular metabolism and used in physiological Read more…
The extracellular components of the skin can be divided into fiber-forming structural molecules, nonfiber-forming structural molecules, and “matricellular proteins”. Optimal quantities of different matrix components and their delicate interactions are necessary to maintain normal physiologic Read more…
We are pleased and proud to welcome Dr Philippe Manivet and Dr Anthony Trezeibre in our Scientific Advisory Board. We are developing new innovative projects with them around our BIOMIMESYS technology. Because our BIOMIMESYS technology Read more…
As a Biomaterials research engineer, you will be valued member of a R&D team focused on the development of cell culture biomaterials from discovery stage to scale up. This role will involve taking significant ownership Read more…
When Tuesday, February 23, 2021 – 1PM (CET) / 8PM (CST) / 9PM (JST) / 7AM (EST) Thursday, February 25, 2021 – 9AM (CET) / 4PM (CST) / 5PM (JST) / 3AM (EST) Where Online, Read more…
Durée : 3 mois minimum Lieu : HCS Pharma, Parc Eurasanté, Loos (59) Missions : Au sein de la société HCS Pharma, vous intégrerez le laboratoire en charge des études en dermocosmétologie qui a pour Read more…
As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.
We wish you a great year 2021, with great success in your all your projects. Here at HCS Pharma, we strongly believed that 3D cell culture in adequat medium is a key factor for successful Read more…
Step by step we are getting closer to 2021, after a very particular and, for some of us, very difficult 2020 year. 2021 will be THE year of 3D cell culture in many research applications Read more…
A publication from R. Lane et al, described the use of Small extracellular vesicles (sEVs) reservoir as a biomarker for Glioblastoma tumor subtyping. In this publication Astrocytes, Glioblastoma cell lines, and Glioblastoma patient-derived stem cells were grown in BIOMIMESYS® hydroscaffold. Read more…
Clinicians and researchers worldwide are actively studying the mechanisms governing the infection of humans by SARS-CoV-2 and its consequences on their health, with the objective is to find effective therapies. We all aknowledge their important Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.